Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Aminah Jatoi, MD is a practicing oncologist at the Mayo Clinic in Rochester, Minnesota, USA. She carries a strong interest in a variety of cancer-related palliative care issues, including the management of weight loss in patients with advanced cancer.
Florian Strasser, MD ABHPM Associate Professor (PD), Head Oncological Palliative Medicine, Clinic for Oncology/Haematology, Dept. Internal Medicine and Palliative Center, Cantonal Hospital St.Gallen, Switzerland, is a medical doctor with board certification in internal medicine, medical oncology and palliative medicine, and dedicates his work to clinical and research activities of integrated oncology and to palliative care and cancer cachexia/nutrition/rehabilitation, as well as capacity building in multi-professional teams.
His interests lie in the development of clinical models, clinical practice tools, and quality indicators to integrate oncology and palliative care. This work is also affiliated with international organizations with functions as chair or other responsibilities in the European Society of Medical Oncology (ESMO), Multinational Association of Supportive Care and Cancer (MASCC), European Association of Palliative Care (EAPC), American Society of Clinical Oncology (ASCO), and The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).
Gustavo de Simone
Gustavo De Simone was born in Argentina in 1955 and graduated as a physician in 1979 completing his specialty in medical oncology. He was appointed Medical Director of the Palliative Care Program at Mainetti Comprehensive Cancer Centre in La Plata, Argentina, in 1991. Since then he has contributed to the development of specialist palliative care services in Buenos Aires and other cities in Argentina. He has led the development of palliative care education mainly at postgraduate level within the University of La Plata, Argentina, from 1992 to 1997 and Universidad del Salvador, Argentina, from 1998 to present, and has been involved in the development of the research and development programs. He is Medical Director of Pallium Latinoamerica Study Centre (NGO), which has had academic links with Oxford International Centre for Palliative Care since 1993.
In June 2005, Dr De Simone was made Coordinator of Post-graduated Training in Palliative Care (Residence Program) within the Ministry of Health, Buenos Aires Government. He is currently Chief of Education and Research Department at the Bonorino Udaondo Public Hospital in Buenos Aires.
In 1998 he became Honorary Professor of Palliative Medicine at the Universidad del Salvador, Buenos Aires, and Director of the Career of Medical Oncology. This is the first Chair in Palliative Medicine in Argentina and provides a focal point for educational developments in South America. Based on his commitments to education, he got the 2003 International Association for Hospice and Palliative Care (IAHPC) Annual “Vittorio Ventafridda Award”.
In 2009 he was made Director of the working group on End of Life Decisions at the Medical Ethics Committee of the National Academy of Medicine, and from 2008 to 2011 he was Argentina's country leader for the EU project “OPCARE9”.
Since 2011 he is the Director of MSc in Palliative Care at the Universidad del Salvador, and has been re-elected President of the Argentinean Association for Palliative Care from 2012 to 2014.
Dr Allan Lipton is Professor of Medicine and Oncology at the MS Hershey Medical Center in Hershey, Pennsylvania, USA. Dr Lipton has a longstanding interest in the natural history and treatment of bone metastases. His group was the first in the USA to treat a patient with pamidronate for bone metastases and also the first in the world to treat patients with zoledronic acid.
Dr Berenson is the founder of the Institute for Myeloma & Bone Cancer Research (IMBCR) and has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.
He serves as a member of the National Institutes of Health - Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.
After receiving a Bachelor of Science with Distinction from Stanford University, USA, he earned his Doctorate in Medicine from the University of California at San Diego, USA. Dr Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center, USA, and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA), USA. He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. He has been affiliated most recently with Cedars-Sinai Medical Center in Los Angeles, USA, and served as the Director of the Multiple Myeloma & Bone Metastasis Programs in the Department of Medicine, Division of Hematology/Oncology. Dr Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as Chief of Medical Oncology and Cancer Research as well as Director of Research at the Greater Los Angeles Veterans Administration Healthcare Systems. Dr Berenson has authored and co-authored numerous books, articles, and abstracts in journals including Blood, Cancer, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, New England Journal of Medicine, and Science.
In addition to his research interests in myeloma and metastatic bone disease, he also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development. Dr Berenson has also conducted numerous clinical trials related to the treatment of multiple myeloma and metastatic bone disease. Because he is internationally known for his expertise and accomplishments in these areas, he has also been asked to give numerous lectures and organize many meetings both nationally and internationally.
Dr Berenson has a private practice which specializes in the treatment of patients with myeloma and metastatic bone disease. He is also President and Chief Executive Officer of Oncotherapeutics, Inc., a corporation that conducts clinical trials related to myeloma and metastatic bone disease as well as other cancers throughout the United States.
Born and raised in Portland, Oregon, Dr Berenson is married to Debra. They have two children, Shira and Ariana.
Dr Berenson's many innovations and successes have included a leader in developing techniques that will rid cancer in stem cells for myeloma patients, discovery of new genes in myeloma bone marrow that will be potential new targets for innovative treatments, development of a new way to sensitively and accurately measure malignant cells which has provided significant improvements in determining the effects of new drugs as well as treatments for tumors, discovery of new treatments for myeloma patients that effectively give a much better quality of life for patients through the significant reduction of toxicity, revolutionized in vivo models making them highly effective to serve as quick ways to optimize drug dosing and treatment techniques for myeloma and bone cancer patients, identified a new herpes virus that is a promising modality to attack myeloma and he has revolutionized research techniques at a genetic level rather than using the traditional protein approach.